Physician profile
Danielle Cara
NPI 1093543159
$2,216.80
in general payments reported to CMS, 2019-2025
21 companies · $1,857 in 2025
The $1,857 reported for 2025 was more than what 95% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $360 · 2025: $1,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,216.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $304.37 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $267.23 | 2024-2025 | |
| Pfizer INC. | $251.89 | 2024-2025 | |
| Novo Nordisk INC | $232.84 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $212.25 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $191.43 | 2025 | |
| Abbott Laboratories | $134.45 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $79.40 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.22 | 2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $69.21 | 2025 | |
| Merck Sharp & Dohme LLC | $61.18 | 2025 | Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $56.46 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $53.02 | 2024-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $47.42 | 2024-2025 | Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.47 | 2025 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $39.91 | 2025 | Voquezna |
| Janssen Biotech, INC. | $30.70 | 2024 | Tremfya |
| Otsuka America Pharmaceutical, INC. | $19.98 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $19.31 | 2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $18.36 | 2025 | Zoryve |
| Tolmar, INC. | $16.70 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Cara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.